Results 111 to 120 of about 2,379 (179)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. [PDF]

Ann Am Thorac Soc
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F, PROMISE Pediatric substudy Investigators.   +13 more
europepmc   +1 more source

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. [PDF]

Clin Transl Sci
Shi A, Agarwal P, Liu ZX, Beringer PM.
europepmc   +1 more source

Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis. [PDF]

Children (Basel)
Álvarez Merino M, Cárdenes CML, Cavia SM, Rubio ET, Rodríguez-Martínez A, Santamaría SV, Torne CV, Beltrán MÁ, Galindo CG, Garriga García M, Alonso AM, Hurtado MM, Sierra San Nicolás S, Ortiz-Pérez P, Gutiérrez Martínez JR, González MS, Jiménez DG, Martín JJD.   +17 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. [PDF]

Eur Respir J
Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, van Koningsbruggen-Rietschel S, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM.   +35 more
europepmc   +1 more source

"An Amazing Transformation!" The Lived Experiences of Elexacaftor/Tezacaftor/Ivacaftor in Adults with Cystic Fibrosis.

Respiration
Chapman N, Vekaria S, Hill K, Cavalheri V, Mulrennan S, Gucciardi DF.   +5 more
europepmc   +1 more source

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Eur Respir J
Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA.   +13 more
europepmc   +1 more source

Hitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis. [PDF]

Am J Respir Crit Care Med
Douglas TA, McMahon SK, Wainwright CE.
europepmc   +1 more source

Comprehensive Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Paediatric Cystic Fibrosis: Nutritional, Pulmonary, and Quality-of-Life Outcomes. [PDF]

J Clin Med
Walicka-Serzysko K, Postek M, Mielus M, Borawska-Kowalczyk U, Milczewska J, Zybert K, Wozniacki Ł, Wołkowicz A, Sands D.   +8 more
europepmc   +1 more source

The effect of elexacaftor-tezacaftor-ivacaftor on liver stiffness in children with cystic fibrosis. [PDF]

J Pediatr Gastroenterol Nutr
Diemer S, Elidottir H, Eklund EA, Påhlman LI, Hansen C.   +4 more
europepmc   +1 more source